Introduction
Electroconvulsive therapy (ECT) is the most effective treatment in major depression. 1, 2 However, the mechanism of the action of ECT is unknown. Several lines of evidence suggest that dopaminergic actions in the prefrontal cortex may be involved. [2] [3] [4] [5] [6] [7] [8] Catechol-O-methyltransferase (COMT) is a major enzyme in dopamine metabolism in the prefrontal cortex. A common functional polymorphism at codon 158 in the gene coding for COMT (COMT Val158Met) results in substantial effects, with Met (low-activity) allele homozygosity leading to a three-to fourfold reduction in enzymatic activity compared with the Val (highactivity) allele homozygosity. 9 Given that ECT has been shown to affect the dopaminergic functions of the prefrontal cortex, COMT is a suitable candidate gene for a pharmacogenetic study. As COMT significantly affects the dopaminergic activity in prefrontal cortex, we hypothesized that COMT polymorphism may be associated with treatment response in ECT.
Results
Patients who had o8 scores in Montgomery and Å sberg Depression Rating Scale (MADRS) 1 were considered responders (n ¼ 45). Scores 415 in MADRS1 indicated nonresponse (n ¼ 32). COMT high/high genotype carriers were more often responders than nonresponders: odds ratio (OR) ¼ 4.366 (95% confidence interval (CI) 1.137-16.770; P ¼ 0.023) ( Table 1) .
Before ECT treatment, MADRS0 scores were not associated with COMT polymorphisms (P40.22, analysis of variance (ANOVA)) ( Figure 1) .
The allele and genotype frequencies from the study population were in Hardy-Weinberg equilibrium.
The effect of initial MADRS scores (MADRS0) on treatment response was studied using univariate analysis of variance. MADRS0 as a covariate did not affect treatment response (P ¼ 0.328). Age, age of onset, sex and the number of ECT treatment did not affect the treatment response (P ¼ 0.170, 0.489, 0.524 and 0.148, respectively).
The concomitant uses of antipsychotics, antidepressants and anxiolytics or hypnotics are shown in Table 2 .
In power analysis the sample size needed for 30% unit difference between responders and nonresponders was 72 (a ¼ 0.05, b ¼ 0.2, power for uncorrected w 2 ¼ 0.6982). This indicates that the sample size of the present study is adequate.
Discussion
The present study is the first to address the impact of COMT polymorphism on treatment response in ECT. We report that the COMT high/high genotype was associated with better treatment response to ECT than were low allelecontaining genotypes. As this functional polymorphism of the COMT gene is associated with dopaminergic activity, we can assume that lower dopamine levels in the prefrontal cortex are associated with substantially better results in ECT.
Our results suggest that COMT high/high genotype carriers are more often responders to ECT than other genotype carriers. High/high genotype is also associated with considerably lower posttreatment MARDS scores. As there is practically no earlier data on an association between COMT and ECT response S Anttila et al COMT and ECT, interpreting our results is difficult. There is a possibility that those patients with depression having less dopaminergic activity in prefrontal cortex (due to highactive COMT enzyme) may respond better to ECT, which in turn increases dopaminergic activity. 2, 10 However, studies of this topic are far from conclusive and further studies are needed to confirm these results.
Our result is in line with Szegedi et al. 11 who reported that COMT high (Val)-allele carriers responded better to treatment with mirtazapine in major depression. In addition, Arias et al. 12 likewise reported that low/low (Met/Met) genotype was associated with increased risk of nonremission in the clinical response to selective serotonin reuptake inhibitors in depressive patients. Thus, it is possible that these three different kinds of treatments have some characteristics in common. However, Szegedi et al.
11 did not find any association between treatment response to paroxetine and COMT polymorphism. Thus, one may suggest that COMT polymorphism is associated with treatment response in major depression only in some cases. However, many more studies are needed before we can conclude which components these different kinds of treatments of depression have in common.
It has been suggested that the effect of the COMT polymorphism in treatment response in depression may be associated with the capability of the COMT enzyme to regulate norepinephrine levels in the brain. 11 However, studies of the role of norepinephrine in ECT have been inconsistent. 10 Moreover, lack of COMT enzyme has not been associated with significant changes in norepinephrine levels in frontal cortex. 13 Thus, the role of norepinephrine may be limited in this context.
Only few studies on the pharmacogenetics of ECT have been published, and with partially conflicting results. [14] [15] [16] [17] Thus, comparison of results with those of the present study is not possible.
The relatively small patient sample is the main limitation of the study. However, we were able to create a naturalistic study and recruit almost all the patients with treatmentresistant major depression who were treated with ECT in this geographical region over a period exceeding 8 years.
Another limitation of the study is the concomitant use of psychotropic drugs during the ECT treatment. However, there are no differences in the use of psychotropic drugs between different COMT polymorphisms ( Table 2 ). This may diminish the effect of drug use on the results of the present study. However, because of insufficient data, we cannot rule out the effect of the concomitant drug use to the results of the present study.
The third limitation is the lack of precise data of the patients' earlier episodes of depression and treatments.
Materials and methods

Patients and controls
A total of 122 patients with Diagnostic and Statistical Manual of Mental Disorders, fourth edition major depressive disorder (MDD) were treated with ECT in the Department of Psychiatry, Tampere University Hospital. Only 3 patients refused and the study group finally consisted of 119 patients (65 women and 54 men). The high recruitment rate is based on several factors as general positive attitude to medical studies in Finland, regular staff in the ECT unit and the contribution of one author (MH).
The patients were consecutively admitted for ECT because of treatment-resistant MDD. Treatment resistance to antidepressants was defined as two or more unsuccessful trials with antidepressants at an adequate dose for at least 4 weeks. Patients with neurological disorders, dementia, schizophrenia, bipolar disorder and alcohol or other substance abuse were excluded. The mean age of the patients was 57.7714.0 years. As much as 27.73% of the patients had the first episode of depression. However, they were treated with ECT only after 0.8271.53 years (range 0-39 years) of suffering from treatment-resistant MDD. There was no difference between MADRS1 in patients who had age-based or stimulus titration method. MADRS1 were 11.0579.12 for age-based method and 11.6178.76 for stimulus titration method (P ¼ 0.745, ANOVA). The patients' demographic data are presented in Table 2 . The blood was drawn when a patient entered the study. All patients gave written informed consent. The study was approved by the Tampere University Hospital Ethics Committee.
Treatment and clinical evaluation ECT was administered three times a week with a brief pulse constant current device (Thymatron DGx, Somatics Inc., Lake Bluff, IL, USA). The initial stimulus dosage was adjusted with the age method for 30 patients. The seizure threshold was determined for 89 patients by administering successive stimuli of increasing intensity until generalized seizure was induced. Anesthesia was induced with methohexital and muscle relaxation with succinylcholine. The initial dose was 1 mg/kg of methohexital and 0.5 mg/kg of succinylcholine. The patients were ventilated with 100% oxygen until resumption of spontaneous respiration. Physiological monitoring included pulse oximetry, blood pressure, electrocardiogram, one-channel electroencephalogram (EEG) and electromyography. The criterion for adequate generalized seizure duration was at least 20 s of motor response and 25 s of EEG seizure activity. If needed, at subsequent treatments during the course of ECT, the dosage was adjusted upward to maintain adequate seizure duration. Electrical dosages were 100% above the seizure threshold. All the patients were treated with standard bilateral (bifrontotemporal) ECT, the number of treatments ranged between 7 and 15, or 9.471.79 (mean7s.d.). The total number of treatments administered was determined by clinical judgment. ECT was continued until patients were free of symptoms or had received at least eight treatments without any further improvement being noted during the past two treatments. The patients received their ongoing medication during the ECT. All except 12 patients had some psychotropic medications (87 had antidepressants, 79 had antipsychotics and 80 had small doses of anxiolytics or hypnotics). Altogether, 55 of the patients had additional no-psychotropic medications during the treatment.
When the study design was determined, there was insufficient research to determine which treatment frequency would be more efficient, two or three times a week. Now we know that they seem to be equally effective. 1 The severity of depression in all patients was assessed by the MADRS before (MADRS0) and after (MADRS1) ECT treatment course. Five experienced psychiatrists assessed the MADRS.
DNA extraction and COMT Val108Met genotyping
Genomic DNA was extracted from peripheral blood leukocytes using commercially available method (Qiagen Inc., Hilden, Germany) and DNA samples were then genotyped by employing the 5 0 exonuclease assay. 18 Primers and allelespecific probes were designed by Applied Biosystems' design service (Foster City, CA, USA). Probes were fluorescently labeled with either FAM (A allele) or VIC (G allele) reported dyes at the 5 0 end. At the 3 0 end, there was a nonfluorescent quencher. PCR reaction mixture consisted of genomic DNA, 1 Â Universal PCR Master Mix, 900 nM of each primer and 200 nM of each probe in a total reaction volume of 25 ml. Amplification was performed in 96-well plates using the TaqMan Universal Thermal Cycling Protocol. After PCR, end-point fluorescence intensity was measured by the ABI Prism 7900HT Sequence Detection System (Applied Biosystems) and allelic discrimination performed resulting in clear identification of three genotypes for the COMT Val108Met polymorphism.
Statistical analysis
Pearson's w 2 -test was used to compare genotypes and allele frequencies between the study groups. The OR was calculated with 95% CI. ANOVA was used to compare means of MADRS1 scores. Univariate analysis of variance was used in covariate analysis. The limit of statistical significance was set at 0.05. Data analysis was carried out using SPSS/Win software (Version 14.0, SPSS Inc., Chicago, IL, USA). Power analysis was performed by PS Power and Sample Size Calculations, Version 2.1.30.
